Table S1 from Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia
Lu Zhang(University of Science and Technology of China), Yu Shen, Weiguo Feng(St. John's University), Daniel H. Albert(AbbVie (United States)), Xiaoli Huang(Shanxi Provincial Institute of Chemical Industry (China)), Marina Konopleva(Albert Einstein College of Medicine), Lloyd T. Lam(National Institutes of Health), Kathleen Dorritie(University of Pittsburgh), Keith F. McDaniel(AbbVie (United States)), Tamar Uziel(AbbVie (United States)), Joshua P. Plotnik(AbbVie (United States)), Gaurav Mehta, Terrance J. Magoc(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), Tianyu Cai(Southwest University of Science and Technology), Vinitha M. Kuruvilla(The University of Texas MD Anderson Cancer Center), Paul Hessler(AbbVie (United States)), Emily J. Faivre(AbbVie (United States)), Antonio Cavazos(The University of Texas MD Anderson Cancer Center), Warren M. Kati(AbbVie (United States)), Neal Goodwin(Champions Oncology (United States)), Sriram S. Shanmugavelandy(AbbVie (United States)), Xiaoyu Lin(AbbVie (United States)), Jenny Rowe(Charles River Laboratories (United States)), Lina Han(Hebei Medical University), Qi Zhang(The University of Texas MD Anderson Cancer Center), Zheng Zha, Xin Lü(Northeast Forestry University), Richard J. Bellin(AbbVie (United States)), Mai H. Bui(AbbVie (United States)), Michael Boyiadzis(UPMC Hillman Cancer Center)
Cited by 0
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Requirement of the MRN complex for ATM activation by DNA damage
|The EMBO Journal|2003|1.1k
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
|Proceedings of the National Academy of Sciences|2008|985
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776